Literature DB >> 22631677

Association between the FAS/FASL polymorphisms and gastric cancer risk: a meta-analysis.

Jing Tian1, Feng Pan, Jing Li, Yan Ma, Han Cen, Hai-Feng Pan, Yue-Yin Pan, Dong-Qing Ye.   

Abstract

OBJECTIVE: FAS/FASL gene promoter polymorphisms have been repeatedly associated with gastric cancer risk, but findings are inconclusive across studies. To address a more precise estimation of the relationship, a meta-analysis was performed.
METHODS: Data were collected from the Pubmed, Medline and EMBASE databases, with the last report up to 1 December, 2011. Crude ORs with 95% CIs were used to assess the strength of the association by (1) the additive, (2) the codominant, (3) the dominant, and (4) the recessive models.
RESULTS: A total of seven studies, including six studies on FAS -1377G>A polymorphism, five studies on FAS -670A>G polymorphism, and six studies on FASL -844T>C polymorphism, were identified in the current meta-analysis. Overall, an association of FAS -1377G>A (AA versus GG: OR = 1.313, 95% CI = 1.045-1.650, Ph = 0.347, I2 = 10.8) and FASL -844T>C (CC versus TT: OR = 1.352, 95% CI = 1.043-1.752, Ph = 0.461, I2 = 0.0) polymorphisms with gastric cancer was found in the codominant model. However, we did not detect any association between gastric cancer and the FAS -670A>G polymorphism. In the subgroup analysis by ethnicity, similar elevated risks were also observed in Asian population for FAS -1377G>A (AA versus GG: OR = 1.309, 95% CI = 1.041- 1.646, Ph = 0.240, I2 = 27.3) and FASL -844T>C (CC versus TT: OR = 1.420, 95% CI = 1.081-1.865, Ph = 0.524, I2 = 0.0) polymorphisms.
CONCLUSIONS: This meta-analysis indicated that FAS -1377G>A and FASL -844T>C polymorphisms might be associated with gastric cancer risk.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22631677     DOI: 10.7314/apjcp.2012.13.3.945

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  8 in total

1.  Quantitative assessment of the association between three polymorphisms in FAS and FASL gene and breast cancer risk.

Authors:  Zexing Wang; Jun Gu; Weiwei Nie; Jing Xu; Guichun Huang; Xiaoxiang Guan
Journal:  Tumour Biol       Date:  2013-11-19

2.  Biomarkers for gastric cancer: Progression in early diagnosis and prognosis (Review).

Authors:  Ziliang Jin; Weihua Jiang; Liwei Wang
Journal:  Oncol Lett       Date:  2015-02-12       Impact factor: 2.967

3.  FasL -844T/C and Fas -1377G/A: mutations of pulmonary adenocarcinoma in South China and their clinical significances.

Authors:  Hongguang Zhao; Wenhu Chen; Peng Du; Aihua Sun; Chenyu Zhuang; Jiali Tong; Lifang Wang
Journal:  Tumour Biol       Date:  2015-01-18

4.  Fas-670A>G polymorphism is not associated with an increased risk of acute myeloid leukemia development.

Authors:  Ying Huang; Donghong Deng; Hongying Li; Qiang Xiao; Lulu Huang; Bing Zhang; Fanghui Ye; Bingbing Ye; Zengnan Mo; Xiaobo Yang; Zhenfang Liu
Journal:  Biomed Rep       Date:  2015-12-31

5.  Non-random distribution of gastric cancer susceptible loci on human chromosomes.

Authors:  Ghazale Mahjoub; Mostafa Saadat
Journal:  EXCLI J       Date:  2018-08-17       Impact factor: 4.068

6.  Genetic polymorphisms and gastric cancer risk: a comprehensive review synopsis from meta-analysis and genome-wide association studies.

Authors:  Jie Tian; Guanchu Liu; Chunjian Zuo; Caiyang Liu; Wanlun He; Huanwen Chen
Journal:  Cancer Biol Med       Date:  2019-05       Impact factor: 5.347

7.  Genomic variants in Fas-mediated apoptosis pathway predict a poor response to Platinum-based Chemotherapy for Chinese Gastric Cancer Patients.

Authors:  Tingting Zhao; Wei Li; Jinfei Chen; Weisong Qin
Journal:  J Cancer       Date:  2021-01-01       Impact factor: 4.207

8.  FAS and FASL gene polymorphisms are not associated with hepatitis B virus infection based on a case-control study in a Brazilian population.

Authors:  Bárbara B Santana; Maria Luana C Viégas; Simone R S S Conde; Marluísa O G Ishak; Ricardo Ishak; Antonio C R Vallinoto
Journal:  Dis Markers       Date:  2013-11-17       Impact factor: 3.434

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.